KalVista Pharmaceuticals (KALV) Short-term Investments (2019 - 2025)

KalVista Pharmaceuticals has disclosed Short-term Investments across 7 years of filings, most recently posting $67.2 million for Q3 2025.

• Short-term Investments for Q3 2025 came in at $67.2 million, down 52.84% year-over-year; the trailing twelve-month figure through Jul 2025 was $67.2 million (down 52.84% YoY), and the FY2025 annual result was $89.0 million, down 50.17% from the prior year.
• Short-term Investments came in at $67.2 million for Q3 2025 at KalVista Pharmaceuticals, down from $89.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $198.3 million in Q2 2021 to a low of $32.6 million in Q1 2021.
• The 5-year median for Short-term Investments is $93.1 million (2023), against an average of $108.3 million.
• Across the five-year window, Short-term Investments soared 357.93% in 2022 and sank 52.84% in 2025, its largest moves.
• KalVista Pharmaceuticals' Short-term Investments stood at $163.3 million in 2021, then tumbled by 48.76% to $83.7 million in 2022, then sank by 45.62% to $45.5 million in 2023, then soared by 89.03% to $86.0 million in 2024, then declined by 21.92% to $67.2 million in 2025.
• The last three Short-term Investments figures came in at $67.2 million (Q3 2025), $89.0 million (Q2 2025), and $86.0 million (Q4 2024), per Business Quant data.